1048 Results for "

drug target

" in MedChemExpress (MCE) Product Catalog:
Products (1048)

1048 Results for "drug target" in MCE Product Catalog:

16
16 Publications Verification
Cat. No.: HY-100421
CAS No.: 1628208-23-0
Purity:  98.31%
Target:  

Histone Demethylase

Research Areas:  

Cancer

CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .
loading...
    loading...
16
16 Publications Verification
Cat. No.: HY-100421A
CAS No.: 2095432-28-1
Target:  

Histone Demethylase

Research Areas:  

Cancer

CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-13631D
CAS No.: 1599440-33-1
Purity:  99.30%
Synonyms: Exatecan derivative for ADC
Research Areas:  

Cancer

DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-132254
CAS No.: 1491917-83-9
Purity:  99.13%
Synonyms: IMMU-132
Research Areas:  

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-132254A
CAS No.: 1491917-83-9
Purity:  96.61%
Synonyms: IMMU-132 (solution)
Research Areas:  

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P99045
CAS No.: 1796566-95-4
Synonyms: HRS7; hRS7
Target:  

ADC Antibodies TROP2

Research Areas:  

Cancer

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P9921A
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)
Research Areas:  

Cancer

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P9921
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine; PRO132365; T-DM 1
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-13822
CAS No.: 312636-16-1
Purity:  99.25%
SKI-II is an orally active dual-target inhibitor of SphK1/2 and DES1, with Ki values of 16 µM and 0.3 µM against SphK1 and DES1, respectively. SKI-II activates the PERK-Nrf2 antioxidant pathway by stabilizing Nrf2, and synergizes with Temozolomide (HY-17364) to induce oxidative/endoplasmic reticulum stress and cancer cell death under hypoxic conditions. In vivo, SKI-II inhibits SphK activity, promotes ceramide accumulation and apoptosis, and synergizes with Cisplatin (HY-17394) to reverse drug resistance via the ras/MAPK pathway. SKI-II reduces measles virus replication by inhibiting mTORC1 activity. SKI-II binds to VCP to induce M1 polarization, enhances host tolerance to Staphylococcus aureus infection, and exerts radioprotective effects through Nrf2 activation and accelerated DNA repair. SKI-II can be used in research related to glioblastoma, acute myeloid leukemia, gastric cancer, measles virus infection, Staphylococcus aureus infection, and acute radiation syndrome .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-17558
CAS No.: 37321-09-8
Synonyms: Nebramycin II
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1329
CAS No.: 65710-07-8
Synonyms: Nebramycin II sulfate
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9985
CAS No.: 2136633-23-1
Synonyms: RC48
Research Areas:  

Cancer

Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0402
CAS No.: 71963-77-4
Synonyms: Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224
Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B1057
CAS No.: 23327-57-3
Synonyms: Fenazoxine hydrochloride
Target:  

β-catenin

Research Areas:  

Neurological Disease Cancer

Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99151
CAS No.: 2088770-90-3
Synonyms: CAC-10

Research Areas:  

Cancer

Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-W441014
Target:  

Liposome

Research Areas:  

Others

DSPE-PEG2000-NHS is a PEG-modified phospholipid derivative that can be used to prepare liposomes. DSPE-PEG2000-NHS is commonly employed as a linker molecule for the surface modification of liposomes to confer targeting capabilities. DSPE-PEG2000-NHS can be used in the study of drug delivery .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-141598B
CAS No.: 2238831-60-0
Synonyms: DS-1062; Dato-DXd
Datopotamab deruxtecan (DS-1062) is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-141598
CAS No.: 2238831-60-0
Purity:  99.54%
Synonyms: DS-1062 (solution); Dato-DXd (solution)
Research Areas:  

Cancer

Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1291
CAS No.: 201422-03-9
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
loading...
    loading...